BioSpace News Archive

Seagen Inc. (Nasdaq:SGEN) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 1:30 p.m. Eastern Time.

BioAtla, Inc. today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company.

ONI, the biotechnology company broadly enabling the ability to observe single molecules in living cells with its desktop Nanoimager microscopy platform, announced that Paul Scagnetti has been appointed as the company’s new CEO, effective February 27, 2023.

IMUNON, Inc.(NASDAQ: IMNN), a clinical-stage biotechnology company, and Break Through Cancer, a public foundation dedicated to empowering outstanding researchers and clinicians to both intercept and find cures for some of the most difficult-to-treat cancers, announces the commencement of patient enrollment in a collaboration to evaluate IMUNON’s IMNN-001 (formerly GEN-1) in combination with bevacizumab in patients with advanced ovarian cancer.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that Rhythm’s Netherlands subsidiary, Rhythm Pharmaceuticals Netherlands B.V. (“Rhythm BV”), acquired Xinvento B.V., a Netherlands-based biotech company focused on developing therapies for congenital hyperinsulinism (CHI).

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 5, 2023, to all shareholders of record as of March 15, 2023.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022.

Histogen Inc. announced the Board of Directors, upon the recommendation of the Company’s Compensation Committee granted Alfred J. Spada, the company’s recently appointed Executive Vice President and Chief Scientific Officer, a nonqualified stock option to purchase 106,793 shares of Histogen Inc. common stock with an exercise price of $1.04 based on the closing price on February 23, 2023, the grant date of the award.

Certara, Inc., a global leader in biosimulation, announced that Company management will participate in the Barclays Global Healthcare Conference.

Zevra Therapeutics, Inc., announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s 2023 Annual Meeting of Stockholders, which is scheduled to take place on April 25, 2023.